首页> 美国卫生研究院文献>BMJ Open >Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
【2h】

Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review

机译:靶向JAK / STAT途径的药物用于治疗免疫介导的炎症性皮肤病:范围审查方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionThe Janus kinase and Signal Transducer and Activator of Transcription protein (JAK/STAT) pathway is known to be involved in inflammatory and neoplastic skin diseases, like psoriasis, atopic dermatitis, alopecia areata, vitiligo and melanoma. Improved knowledge of the components of this pathway has allowed the development of drugs, which act by inhibiting the pathway, blocking specific components. This offers new therapeutic opportunities. Although evidence on the use of JAK/STAT blockades in dermatological diseases is growing, none have been approved for use in treating skin diseases. The aim of this study is to develop an a priori protocol to broadly review the available evidence on the use of drugs targeting the JAK/STAT pathway in the treatment of dermatological diseases.
机译:简介Janus激酶以及信号转导和转录激活因子(JAK / STAT)通路已知与炎症和肿瘤性皮肤病有关,例如牛皮癣,特应性皮炎,斑秃,白癜风和黑色素瘤。对这种途径成分的了解的提高使药物的开发成为可能,该药物通过抑制途径,阻断特定成分而发挥作用。这提供了新的治疗机会。尽管有关在皮肤病中使用JAK / STAT阻滞剂的证据正在增长,但尚未批准将其用于治疗皮肤病。这项研究的目的是开发一种先验方案,以广泛地审查有关在皮肤病治疗中使用靶向JAK / STAT途径的药物的现有证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号